Patient Guide: Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 10 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05469360
Status: 🟢 Enrolling Now
Condition: Alzheimer Disease, Mild Cognitive Impairment
Phase: PHASE1

Where You Can Participate

This study is available at 10 locations across the country.

Top locations include:
  • • Kuopio,
  • • Turku,
  • • Lille,
  • • And 7 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants - Join Clinical Trial NCTNCT05469360

How to Join This Clinical Trial - NCTNCT05469360

Learn how to participate in this PHASE1 trial studying an investigational therapy for Alzheimer Disease, Mild Cognitive Impairment. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Alzheimer Disease, Mild Cognitive Impairment. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Alzheimer Disease, Mild Cognitive Impairment
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05469360 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 10 locations. Find a study site near you:

Clinical Research Site

Kuopio, 70210 - Finland

Status: COMPLETED

Clinical Research Site

Turku, 20520 - Finland

Status: COMPLETED

Clinical Research Site

Lille, 59037 - France

Status: RECRUITING

Clinical Research Site

Paris, 75013 - France

Status: RECRUITING

Clinical Research Site

Toulouse, 31059 - France

Status: RECRUITING

Clinical Research Site

Valencia, Valencia 46017 - Spain

Status: RECRUITING

Clinical Research Site

Barcelona, 08036 - Spain

Status: RECRUITING

Clinical Research Site

Barcelona, 08041 - Spain

Status: RECRUITING

Clinical Research Site

Malmo, 221 85 - Sweden

Status: COMPLETED

Clinical Research Site

Stockholm, 141 86 - Sweden

Status: COMPLETED

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Alzheimer Disease, Mild Cognitive Impairment:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships